肺移植受者非结核分枝杆菌分离的结局:匹配病例对照与回顾性队列研究
该研究在大型移植中心7年间对肺移植受者中培养阳性的非结核分枝杆菌(NTM)病例进行1:2匹配病例对照分析。治疗病例中不良事件和药物相互作用常见,57.1%因之早期停药。
要点
- 肺移植受者NTM分离多不符合指南诊断标准,结局与非感染患者相似,可能反映短暂定植而非真性疾病。
- 治疗病例中不良事件和药物相互作用发生率超过90%,57.1%因之早期停药。
- 限制不必要的NTM抗生素治疗是抗菌药物管理的重要方向。
核心结论
- 肺移植受者中多数NTM分离病例不符合指南感染标准,结局与非NTM感染患者相似,可能反映NTM短暂肺部定植而非真性疾病。
- NTM治疗不良事件常见,限制不必要的抗生素治疗是未来抗菌药物管理的方向。
研究设计与样本
- 在大型移植中心开展7年期间(2013-2019)肺移植受者NTM培养阳性病例的病例对照研究。
主要发现
- NTM分离中位时间为移植后10.7个月。
- 仅34.5%的病例符合NTM肺部感染诊断标准,治疗病例中仅一半符合。
- 12个月全因死亡率NTM病例数值上高于对照(20.7% vs 8.6%,P=0.169),但无死亡归因于NTM。
- 12个月急性排斥率无增加(27.6% vs 36.2%,P=0.477)。
- 近期增强免疫抑制与NTM分离 odds 增加相关,阿奇霉素预防与NTM分离 odds 降低相关且与宏内酯耐药无关。
关键数值与推荐
- 仅34.5%的NTM分离病例符合指南NTM肺部感染诊断标准。
- 治疗病例中不良事件和实际或潜在药物相互作用发生率超过90%,包括眼毒性、听力损失和超治疗浓度钙调神经磷酸酶抑制剂。
- 14例治疗病例中8例(57.1%)因不良事件或药物相互作用需早期停用抗生素。
临床怎么用
- 肺移植受者NTM分离时需评估是否符合指南诊断标准,避免不必要的抗生素治疗。
- 启动NTM治疗时应密切监测不良事件和药物相互作用,尤其是钙调神经磷酸酶抑制剂浓度。
- 阿奇霉素预防可能与降低NTM分离风险相关,且未增加宏内酯耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lung transplant recipients are at increased risk for acquiring nontuberculous mycobacteria (NTM), but the clinical significance of NTM isolation, particularly among patients not meeting guideline-endorsed diagnostic criteria for NTM pulmonary disease, is unclear. METHODS: A case-control study of lung transplant recipients culture-positive for NTM at a large transplant center during a 7-year period (2013-2019) was performed. RESULTS: Twenty-nine cases were matched 1:2 to non-NTM controls. The median time to NTM isolation was 10.7 months post transplant. Only 34.5% of all cases, and half of treated cases, met diagnostic criteria for NTM pulmonary infection. All-cause mortality at 12 months was numerically higher among NTM cases versus controls (20.7% vs 8.6%, P = 0.169); however, no deaths were attributed to NTM. No increase in the 12-month rate of acute rejection was observed (27.6% vs 36.2%, P = 0.477). Recent augmented immunosuppression was associated with increased odds of NTM isolation, while azithromycin prophylaxis was associated with reduced odds of NTM isolation and was not associated with macrolide resistance. Both adverse events and actual or potential drug-drug interactions occurred in more than 90% of treated cases; these events included ocular toxicity, hearing loss, and supratherapeutic calcineurin inhibitor concentrations. Eight of the 14 treated cases (57.1%) required early antibiotic discontinuation due to adverse events or drug-drug interactions. CONCLUSION: Among lung transplant recipients, most patients with NTM isolation did not meet guideline criteria for infection and had outcomes similar to non‒NTM-infected patients, which may reflect transient lung colonization by NTM rather than true disease. As adverse events are common with NTM therapy, limiting unnecessary antibiotic treatment represents an area for future antimicrobial stewardship efforts.
引用
- Grimes R, Cherrier L, Nasar A, et al. Outcomes of nontuberculous mycobacteria isolation among lung transplant recipients: A matched case-control with retrospective cohort study. Am J Health Syst Pharm. 2022. PMID: 34634122. doi:10.1093/ajhp/zxab389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。